Abstract Details

Title Prognosis after Status Epilepticus

Topic Epilepsy

Presentation(s) P07 - (-)

Poster/Presentation
Number 175

Objective

Background BACKGROUND: SE is a neurological emergency with significant mortality and morbidity. There is currently limited data regarding the causes and outcomes of SE in our locality.

Design/Methods DESIGN/METHODS: We retrospectively studied the clinical characteristics, clinical outcome of adults diagnosed with convulsive SE and managed at a regional hospital in Hong Kong during January 1st 2007 - December 31st 2011.

Results RESULTS: A total of 38 patients with convulsive SE were identified during the study period. The mean age was 58 years (range 21-92 years) and 61% were males. Underlying cerebrovascular disease (34%), poor compliance to anti-convulsants in patients with known epilepsy (16%) and infection of the central nervous system (11%) were the main causes of convulsive SE. SE was associated with 21% mortality during hospitalization period and 32% mortality within 6-months of admission. Age?65 years, prior history of seizures, a higher blood glucose level during SE and a Status Epilepticus Severity Score (STESS) ?4 were associated with 6-month mortality (p<0.05). Multi-variate analysis subsequently identified a STESS?4 as an independent predictor of poor prognosis (p=0.03).

Conclusions CONCLUSIONS: Convulsive SE in adults is most commonly due to underlying cerebrovascular disease and is associated with a high mortality. The STESS is a useful tool in predicting 6-month mortality.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Raymond T. Cheung, MD, FAAN (University of Hong Kong)	No disclosure on file
Shu Leong Ho, MD, FAAN (Gleneagles Hospital Hong Kong)	No disclosure on file
	No disclosure on file
Gary K. Lau, MBBS (University of Hong Kong)	Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Daiichi Sankyo. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Amgen. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Boehringer Ingelheim. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Daiichi Sankyo. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Pfizer. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Eisai. Dr. Lau has stock in ReMobility. The institution of Dr. Lau has received research support from Croucher Foundation. The institution of Dr. Lau has received research support from Research Fund Secretariat of the Food and Health Bureau, Hong Kong. The institution of Dr. Lau has received research support from Innovation and Technology Bureau, Hong Kong. The institution of Dr. Lau has received research support from Research Grants Council, Hong Kong. Dr. Lau has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��